A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS) Meeting Abstract

  

Authors:	Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S.; Reed, D. R.; Okuno, S. H.; Ludwig, J. A.; Hande, K. R.; Rietschel, P.; Kraft, A. S.; Adkins, D.; Brockstein, B.; Yim, V.; Bitas, C.; Antonescu, C.; Maki, R. G.
Abstract Title:	A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS)
Meeting Title:	48th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	30
Issue:	15 Suppl.
Meeting Dates:	2012 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2012-05-20
Language:	English
ACCESSION:	WOS:000318009802240
PROVIDER:	wos
DOI:	10.1200/jco.2012.30.15_suppl.10003
Notes:	Meeting Abstract: 10003 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/152173